S. P. A. Aptafin - 30 Jun 2021 Form 3 Insider Report for REGENERX BIOPHARMACEUTICALS INC

Role: Member of 10% owner group
Signature: /s/ Emanuela Belletti, Chief Executive Officer
Issuer symbol: RGRX on OTC
Transactions as of: 30 Jun 2021
Net transactions value: $0
Form type: 3
Filing time: 19 Jul 2021, 16:15:17 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	RGRX	Common Stock						1,500,000	30 Jun 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	RGRX	Common Stock Warrant (right to buy)							30 Jun 2021	Common Stock	1,125,000	$0.2400	Direct	F1, F2
holding	RGRX	Common Stock Warrant (right to buy)							30 Jun 2021	Common Stock	1,125,000	$0.2800	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 30, 2021, in a private placement by the issuer, Aptafin S.p.A. ("Aptafin") entered into a purchase agreement, pursuant to which it agreed to purchase 1,500,000 shares of the common stock of the issuer and warrants to acquire the issuer's common stock, for an aggregate purchase price of $300,000. Aptafin is filing this Form 3 as it has now been able to regenerate the necessary Edgar codes. A Form 4 with respect to this transaction was filed by Paolo Cavazza on July 2, 2021. Mr. Cavazza owns 99% of the equity interests of Apta Finance SA, which in turn owns 100% of the equity interests of Aptafin. Mr. Cavazza may be deemed to indirectly beneficially own the securities of the issuer purchased by Aptafin.
F2	Aptafin received two different warrants in the transaction, one of which is exercisable, in whole or in part, at any time and from time to time, from June 30, 2021 through June 30, 2023, for up to 1,125,000 shares of common stock of the issuer at an exercise price of $0.24 per share, and one of which is exercisable, in whole or in part, at any time and from time to time, from June 30, 2021 through June 30, 2026, for up to 1,125,000 shares of common stock of the issuer at an exercise price of $0.28 per share.

Content

On June 30, 2021, in a private placement by the issuer, Aptafin S.p.A. ("Aptafin") entered into a purchase agreement, pursuant to which it agreed to purchase 1,500,000 shares of the common stock of the issuer and warrants to acquire the issuer's common stock, for an aggregate purchase price of $300,000. Aptafin is filing this Form 3 as it has now been able to regenerate the necessary Edgar codes. A Form 4 with respect to this transaction was filed by Paolo Cavazza on July 2, 2021. Mr. Cavazza owns 99% of the equity interests of Apta Finance SA, which in turn owns 100% of the equity interests of Aptafin. Mr. Cavazza may be deemed to indirectly beneficially own the securities of the issuer purchased by Aptafin.

Aptafin received two different warrants in the transaction, one of which is exercisable, in whole or in part, at any time and from time to time, from June 30, 2021 through June 30, 2023, for up to 1,125,000 shares of common stock of the issuer at an exercise price of $0.24 per share, and one of which is exercisable, in whole or in part, at any time and from time to time, from June 30, 2021 through June 30, 2026, for up to 1,125,000 shares of common stock of the issuer at an exercise price of $0.28 per share.